Search icon

AUCTUS BIOLOGICS, INC.

Company claim

Is this your business?

Get access!

Company Details

Name: AUCTUS BIOLOGICS, INC.
Jurisdiction: New York
Legal type: FOREIGN BUSINESS CORPORATION
Status: Active
Date of registration: 05 Jul 2018 (7 years ago)
Entity Number: 5370637
ZIP code: 13084
County: Onondaga
Place of Formation: Delaware
Address: 2561 US RT 11, LAFAYETTE, NY, United States, 13084

DOS Process Agent

Name Role Address
THE CORPORATION DOS Process Agent 2561 US RT 11, LAFAYETTE, NY, United States, 13084

Chief Executive Officer

Name Role Address
KELSEY MOODY Chief Executive Officer 2561 US RT 11, LAFAYETTE, NY, United States, 13084

History

Start date End date Type Value
2024-07-12 2024-07-12 Address 2561 US RT 11, LAFAYETTE, NY, 13084, USA (Type of address: Chief Executive Officer)
2018-07-05 2024-07-12 Address 2521 US ROUTE 11, LAFAYETTE, NY, 13084, USA (Type of address: Service of Process)

Filings

Filing Number Date Filed Type Effective Date
240712002918 2024-07-12 BIENNIAL STATEMENT 2024-07-12
220216003707 2022-02-16 BIENNIAL STATEMENT 2022-02-16
180705000407 2018-07-05 APPLICATION OF AUTHORITY 2018-07-05

USAspending Awards / Financial Assistance

Date:
2022-02-09
Awarding Agency Name:
National Science Foundation
Transaction Description:
SBIR PHASE I: DEVELOPMENT OF AN OPTICAL BIOSENSOR TO FACILITATE SCREENING, VALIDATION, AND DEVELOPMENT OF NOVEL DRUGS AND THEIR BIOLOGICAL TARGETS -THE BROADER IMPACT OF THIS SMALL BUSINESS INNOVATION RESEARCH (SBIR) PHASE I PROJECT WILL IMPROVE DRUG DISCOVERY. THE PROPOSED PROJECT WILL ADVANCE THE DEVELOPMENT OF SURFACE PLASMON RESONANCE (SPR), A NOVEL OPTICAL BIOSENSOR TECHNOLOGY, THAT WILL ACCELERATE THE PACE AND EFFICIENCY OF DRUG SCREENING CAMPAIGNS IN ACADEMIA AS WELL AS THE PHARMACEUTICAL AND BIOTECHNOLOGY INDUSTRIES. THERE ARE CURRENTLY NO BIOSENSOR TECHNOLOGIES ON THE MARKET THAT OFFER THE COMBINATION OF HIGH SENSITIVITY, ROBUST REUSABILITY, ANTIBODY-LIKE BINDING AFFINITY, AND LOW COST. THIS PROJECT WILL CULMINATE IN THE DEVELOPMENT OF A TECHNOLOGY AND REAGENT-BASED KITS FOR APPLICATIONS AT SCALE. THE PROPOSED PROJECT ADVANCES A TECHNOLOGY ENGINEERED FROM A TEMPERATURE, PH, AND CHEMICALLY STABLE PROPRIETARY PROTEIN COMPOSED OF TWO FRAGMENTS THAT BIND WITH ANTIBODY-LIKE AFFINITY AND SPECIFICITY. THE TECHNOLOGY HAS BEEN DEMONSTRATED TO BE EFFECTIVE IN A VARIETY OF ANTIBODY-LIKE APPLICATIONS, BUT WITHOUT THE STABILITY SHORTCOMINGS THAT PLAGUE TRADITIONAL ANTIBODIES. BY OVERCOMING KEY BARRIERS THAT LIMIT LARGE-SCALE USE OF SPR CHIPS, THIS TECHNOLOGY ENABLES CHIP REUSE AND STREAMLINES LABORATORY WORKFLOWS, THUS ENDOWING THE SYSTEM WITH BROAD UTILITY IN ANTIBODY-CENTERED APPLICATIONS. THE PROJECT HAS THREE GOALS: ESTABLISH SUITABILITY OF THE TECHNOLOGY FOR THE COMPLETE CHARACTERIZATION OF MOLECULAR INTERACTION PAIRS, EVALUATE THE TECHNOLOGY?S ROBUSTNESS AND VERSATILITY, AND VALIDATE THE TECHNOLOGY IN DRUG SCREENING CAMPAIGNS. THIS AWARD REFLECTS NSF'S STATUTORY MISSION AND HAS BEEN DEEMED WORTHY OF SUPPORT THROUGH EVALUATION USING THE FOUNDATION'S INTELLECTUAL MERIT AND BROADER IMPACTS REVIEW CRITERIA.
Obligated Amount:
228697.00
Face Value Of Loan:
0.00
Total Face Value Of Loan:
0.00

Reviews Leave a review

This company hasn't received any reviews.

Date of last update: 23 Mar 2025

Sources: New York Secretary of State